NEWS 
& MEDIA

MEDIA
CONTACT

Welcome to the Takeda Oncology Newsroom. This section is dedicated to providing the most up-to-date information about our company, our people and our science.

If you are a reporter, please contact:
Phone: 617-444-1400
Email: TakedaOncologyNews@takeda.com

For other Takeda news releases, please visit the Takeda.com Newsroom. 

GO TO TAKEDA NEWSROOM

NEWS
RELEASES

5/14/2020

Takeda China announces ADCETRIS® (brentuximab vedotin) is approved for the treatment of adult patients with CD30-positive Lymphomas

READ MORE  
5/14/2020

European Commission Approves ADCETRIS® (brentuximab vedotin) for Treatment of Adult Patients with Previously Untreated Systemic Anaplastic Large Cell Lymphoma

READ MORE  
4/27/2020

Takeda Announces U.S. FDA Breakthrough Therapy Designation for Mobocertinib (TAK-788) for the Treatment of NSCLC Patients with EGFR Exon 20 Insertion Mutations

READ MORE